78.72 USD
↗ 0.04 (0.06%)LIVE (AS OF 09:36 AM EDT)
Kiniksa Pharmaceuticals International, plc Class A Ordinary Shares
KNSANASDAQ • USD
Market: OPEN
Shares of Kiniksa Pharmaceuticals International, plc Class A Ordinary Shares (KNSA) are trading at $78.72. Both sides of the analysis agree: technicals flash "Buy" and fundamentals confirm with a "Buy" reading. Notable factors include a robust Altman Z-Score, a bullish Golden Cross on the moving averages and bullish moving average alignment. Valuation-wise, the stock is priced at a premium — multiples like P/E and EV/EBITDA sit above sector averages.
Technical & fundamental data as of Aug 26, 2026.
Open?$78.99
High?$79.57
Low?$78.19
Prev. Close?$78.68
Volume?13.5K
Avg. Volume?622.6K
VWAP?$78.82
Rel. Volume?0.02x
Bid / Ask
Bid?$67.24 × 100
Ask?$90.81 × 100
Spread?$23.57
Midpoint?$79.03
Valuation & Ratios
Market Cap?6.1B
Shares Out?48.3M
Float?38.9M
Float %?84.2%
P/E Ratio?76.11
P/B Ratio?9.38
EPS?$1.03
Dividend?0.39%
Ex-Dividend?N/A
News
Profile
Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating cardiovascular diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and Vixarelimab. Geographically, the company earns maximum revenue from United States.
Address
105 PICCADILLY, SECOND FLOOR
LONDON, W1J 7NJ
Phone: (781) 431-9100
LONDON, W1J 7NJ
Phone: (781) 431-9100
Technical OutlookBuy
Strong SellNeutralStrong Buy
Long-Term (Tide)?▲ Bullish(+2/3)
Medium-Term (Wave)?– Neutral(0/3)
Short-Term (Ripple)?▼ Bearish(-2/3)
MA Alignment?Golden Alignment
Full Technical Analysis →Fundamental OutlookBuy
Strong SellNeutralStrong Buy
F-Score?60
Z-Score?100
Momentum?73
Short Sent.?54
Piotroski F-Score?5/9Mixed
Altman Z-Score?16.55Safe
Confidence?68%Moderate
Short InterestHigh
Short % of Float?11.01%High
Short Interest?4.3M
Days to Cover?9.6
Free Float38.9M
Avg Daily Volume448.0K
Settlement Date2026-08-14
Financial Health
Current Ratio?3.90Strong
Quick Ratio?3.49Strong
Cash Ratio?1.03Strong
Debt/Equity?0.13Low
ValuationRICHLY VALUEDvs 1 peers + S&P 500
Score39/100
P/E?76.1PRICEY▾
Peers100
S&P5
P/B?9.38HIGH▾
Peers100
S&P20
P/S?7.30HIGH▾
Peers100
S&P16
P/FCF?33.6FAIR▾
Peers100
S&P23
EV/EBITDA?59.3HIGH▾
Peers100
S&P3
EV/Sales?7.20HIGH▾
Peers100
S&P19
Returns & Efficiency
ROE?12.3%STRONG▾
Peers50
S&P44
ROA?9.0%STRONG▾
Peers50
S&P71
Cash Flow & Enterprise
FCF?$182.8M
Enterprise Value?$6.1B
Fundamentals ratios updated end of day